Neurogene Inc.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company's common stock to one new employee (the “Inducement Grant”) on November 3, 2026 (the “Grant Date”). The Induceme.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, November 10 at 10:30 a.m. ET Stifel 2026 Healthcare Conference Forma.

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, will present data related to its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. The new preclinical data are expected to further validate NGN-401's differentiated desig.

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings. Analyst Ratings This is a breakdown of recent

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. New preclinical data to be featured are aimed at addressing two import.

Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) saw unusually-high trading volume on Monday. Approximately 109,919 shares were traded during mid-day trading, a decline of 46% from the previous session's volume of 205,269 shares. The stock last traded at $26.7650 and had previously closed at $26.40. Wall Street Analyst Weigh In NGNE has been

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company's common stock to five new employees (the “Inducement Grants”) on October 5, 2026 (the “Grant Date”). The Induce.

Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Ratings This is a summary of

Bank of New York Mellon Corp acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 28,741 shares of the company's stock, valued at approximately $904,000. Bank of

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, September 15 at 1:00 p.m. ET A live webcast of the fireside chat will be accessible from.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company's common stock to two new employees (the “Inducement Grants”) on September 1, 2026 (the “Grant Date”). The Indu.

BlackRock Inc. acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) in the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,057,983 shares of the company's stock, valued at approximately $33,274,000. BlackRock Inc. owned about 6.70% of Neurogene at the end of the most

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2026 financial results and highlighted recent corporate updates. “The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term Phase 1/2 data showing durable, multidomain developmental gains that have not be.